JP2014510755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510755A5 JP2014510755A5 JP2014502770A JP2014502770A JP2014510755A5 JP 2014510755 A5 JP2014510755 A5 JP 2014510755A5 JP 2014502770 A JP2014502770 A JP 2014502770A JP 2014502770 A JP2014502770 A JP 2014502770A JP 2014510755 A5 JP2014510755 A5 JP 2014510755A5
- Authority
- JP
- Japan
- Prior art keywords
- azacytidine
- salt
- protected
- acid
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470392P | 2011-03-31 | 2011-03-31 | |
| US61/470,392 | 2011-03-31 | ||
| PCT/US2012/031059 WO2012135405A1 (en) | 2011-03-31 | 2012-03-29 | Systhesis of 5-azacytidine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510755A JP2014510755A (ja) | 2014-05-01 |
| JP2014510755A5 true JP2014510755A5 (https=) | 2015-05-07 |
| JP6289361B2 JP6289361B2 (ja) | 2018-03-07 |
Family
ID=46000343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502770A Active JP6289361B2 (ja) | 2011-03-31 | 2012-03-29 | ５−アザシチジンの合成 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9951098B2 (https=) |
| EP (1) | EP2691408B1 (https=) |
| JP (1) | JP6289361B2 (https=) |
| KR (1) | KR20140019820A (https=) |
| CN (1) | CN103619864A (https=) |
| AU (1) | AU2012236476A1 (https=) |
| BR (1) | BR112013025167A2 (https=) |
| IL (1) | IL228604A0 (https=) |
| MX (1) | MX2013010945A (https=) |
| RU (1) | RU2013148580A (https=) |
| SG (1) | SG193622A1 (https=) |
| WO (1) | WO2012135405A1 (https=) |
| ZA (1) | ZA201307142B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782612B1 (en) | 2008-05-15 | 2023-11-08 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| WO2012106299A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| US9968627B2 (en) | 2013-03-26 | 2018-05-15 | Celgene Corporation | Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof |
| WO2014169216A2 (en) | 2013-04-11 | 2014-10-16 | Carnegie Mellon University | TEMPLATE-DIRECTED γPNA SYNTHESIS AND γPNA TARGETING COMPOUNDS |
| WO2014169206A2 (en) | 2013-04-11 | 2014-10-16 | Carnegie Mellon University | Divalent nucleobase compounds and uses therefor |
| CN103450303A (zh) * | 2013-09-04 | 2013-12-18 | 重庆泰濠制药有限公司 | 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法 |
| CN104672289A (zh) * | 2013-11-29 | 2015-06-03 | 南京圣和药业股份有限公司 | 一种阿扎胞苷杂质的制备方法 |
| WO2017183215A1 (ja) * | 2016-04-21 | 2017-10-26 | 大原薬品工業株式会社 | ５－アザシチジン類の糖部シリルエーテル誘導体 |
| CN114907272A (zh) | 2016-09-26 | 2022-08-16 | 卡耐基梅隆大学 | 二价核碱基化合物及其用途 |
| CN109305992A (zh) * | 2017-07-28 | 2019-02-05 | 江苏先声药业有限公司 | 一种阿扎胞苷的制备方法 |
| CN109988207B (zh) * | 2017-12-29 | 2022-01-04 | 江苏豪森药业集团有限公司 | 阿扎胞苷晶型的制备方法 |
| CN110092807A (zh) * | 2018-01-30 | 2019-08-06 | 中国医学科学院药物研究所 | 一种高纯、低灼烧残渣的制备阿扎胞苷的方法 |
| JP7017638B2 (ja) | 2018-02-07 | 2022-02-08 | ラブレス バイオメディカル リサーチ インスティテュート | 吸入可能な乾燥粉末シチジン類似体組成物及び癌への治療として使用する方法 |
| KR20190136284A (ko) * | 2018-05-30 | 2019-12-10 | 주식회사 삼양바이오팜 | 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 |
| WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
| BR112022022243A2 (pt) | 2020-05-01 | 2022-12-20 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19. |
| CN113201039B (zh) * | 2021-05-19 | 2022-04-29 | 南京德克瑞医药化工有限公司 | 一种医药中间体2’,3’,5’-三乙酰阿扎胞苷的制备方法 |
| AR134497A1 (es) | 2023-11-28 | 2026-01-21 | Sanofi Sa | Combiterapia multifuncional con activador de los linfocitos citolíticos naturales (nk) para tratar trastornos neoplásicos hemáticos |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1050899A (https=) | 1963-12-22 | |||
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| CH507969A (de) | 1968-11-12 | 1971-05-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| DE2012888C3 (de) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| FR2123632A6 (en) | 1971-01-26 | 1972-09-15 | Ceskoslovenska Akademie Ved | Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine |
| DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
| DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| DE2757365A1 (de) | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| IL129126A0 (en) * | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| AU2003278904A1 (en) | 2002-09-24 | 2004-04-19 | Kornis Pharmaceuticals, Incorporated | 1, 3, 5-triazines for treatment of viral diseases |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| CA2535889A1 (en) | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| EP2644614A3 (en) | 2007-01-11 | 2014-02-26 | IVAX Pharmaceuticals s.r.o. | Solid state forms of 5-azacytidine and processes for preparation thereof |
| US20110288042A1 (en) | 2007-08-02 | 2011-11-24 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
| EP2048151A1 (en) | 2007-10-10 | 2009-04-15 | Cilag AG | Method for producing nucleosides by direct glycosylation of the nucleoside base |
| EP2211870A1 (en) | 2007-11-01 | 2010-08-04 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| EP3782612B1 (en) | 2008-05-15 | 2023-11-08 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| WO2010014883A2 (en) | 2008-08-01 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
| EP2324042B1 (en) | 2008-08-06 | 2012-11-28 | Sicor, Inc. | Process for preparing azacytidine intermediate |
| AR073003A1 (es) | 2008-08-08 | 2010-10-06 | Scinopharm Taiwan Ltd | Proceso para preparar 5-azacitosina nucleosidos y sus derivados |
| US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
| IT1399195B1 (it) | 2010-03-30 | 2013-04-11 | Chemi Spa | Processo per la sintesi di azacitidina e decitabina |
-
2012
- 2012-03-29 MX MX2013010945A patent/MX2013010945A/es not_active Application Discontinuation
- 2012-03-29 AU AU2012236476A patent/AU2012236476A1/en not_active Abandoned
- 2012-03-29 WO PCT/US2012/031059 patent/WO2012135405A1/en not_active Ceased
- 2012-03-29 BR BR112013025167A patent/BR112013025167A2/pt not_active IP Right Cessation
- 2012-03-29 JP JP2014502770A patent/JP6289361B2/ja active Active
- 2012-03-29 CN CN201280026401.3A patent/CN103619864A/zh active Pending
- 2012-03-29 US US14/007,955 patent/US9951098B2/en active Active
- 2012-03-29 EP EP12716820.1A patent/EP2691408B1/en active Active
- 2012-03-29 KR KR1020137028446A patent/KR20140019820A/ko not_active Withdrawn
- 2012-03-29 SG SG2013071915A patent/SG193622A1/en unknown
- 2012-03-29 RU RU2013148580/04A patent/RU2013148580A/ru not_active Application Discontinuation
-
2013
- 2013-09-23 ZA ZA2013/07142A patent/ZA201307142B/en unknown
- 2013-09-29 IL IL228604A patent/IL228604A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510755A5 (https=) | ||
| RU2013148580A (ru) | Синтез 5-азацитидина | |
| CN106061972B (zh) | 5-氟-4-亚氨基-3-(烷基/取代烷基)-1-(芳基磺酰基)-3,4-二氢嘧啶-2(1h)-酮及其制备方法 | |
| TWI657088B (zh) | 製造稠合雜環化合物之方法 | |
| TWI663160B (zh) | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 | |
| TWI658042B (zh) | 雜環化合物的合成 | |
| JP2015530367A5 (https=) | ||
| JP2014521726A5 (https=) | ||
| JP2013505259A5 (https=) | ||
| TWI739871B (zh) | 新化合物及方法 | |
| JP2010503694A5 (https=) | ||
| JP2010505926A5 (https=) | ||
| JP2013535220A5 (https=) | ||
| JP2014501790A5 (https=) | ||
| JP2018502909A5 (https=) | ||
| JP2013518092A5 (https=) | ||
| RU2014126224A (ru) | Способ получения и очистки солей акриламидо-2-метилпропансульфоновой кислоты | |
| JP7144873B2 (ja) | スガマデクスナトリウム塩の製造方法 | |
| US9624258B2 (en) | Polymorph of regadenoson | |
| WO2017221214A1 (en) | Crystalline forms of salts of lenvatinib | |
| TWI545114B (zh) | 製備聯苯基咪唑化合物之方法 | |
| JP2010512392A5 (https=) | ||
| JP5315335B2 (ja) | トポテカンの製造方法 | |
| JP2014520796A5 (https=) | ||
| KR102702677B1 (ko) | 피마살탄 및 그의 제조 중간체의 제조방법 |